For the Inventor, By the Inventor

Enter assignee name

Geneva, Switzerland

Novimmune Sa

USPTO Granted Patents = 64

CIPO Patents = 8

EPO Patents = 23

Trademarks = 3

Forward Citations = 409

Loading Chart...

Loading Chart...

51 inventors (with patents filed for the assignee):

Greg Elson (35 out of 36 patents)

Nicolas Fischer (31 out of 32 patents)

Olivier Leger (26 out of 28 patents)

4. Marie Kosco-Vilbois (24 out of 30 patents)

5. Krzysztof Masternak (13 out of 14 patents)

6. Giovanni Magistrelli (11 out of 11 patents)

7. Francois Rousseau (10 out of 11 patents)

8. Walter Ferlin (9 out of 9 patents)

9. Franck Gueneau (6 out of 6 patents)

10. Ulla Ravn (6 out of 6 patents)

11. Florence Guilhot (6 out of 6 patents)

12. Bernard Francois Mach (6 out of 9 patents)

13. Pauline Malinge (4 out of 4 patents)

14. Yann Dean (4 out of 6 patents)

15. Limin Shang (4 out of 4 patents)

Core Competencies:

Bispecific Antibodies

Anti-CD47 Antibodies

Anti-IL-6 Antibodies

Multispecific Antibodies

Neutralizing Antibodies

Anti-CD3 Antibodies

Anti-TLR4 Antibodies

Antibody Drug Conjugates

Polypeptide Libraries

Chimeric Polypeptides

Autoimmune Diseases

Cross-Reactive Antibodies

64 patents: Sort by Forward Citations

1. 12448444 - Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof (2025-10-21),

2. 11840553 - Anti-CD47 antibodies and methods of use thereof (2023-12-12),

3. 11827703 - Compositions and methods related to anti-CD19 antibody drug conjugates (2023-11-28),

4. 11613582 - Anti-IL-6/IL-6R antibodies and methods of use thereof (2023-03-28),

5. 11401299 - Generating multispecific antibody mixtures and methods of uses thereof (2022-08-02),

6. 11261262 - Readily isolated bispecific binding molecules with native format having mutated constant regions (2022-03-01),

7. 11260117 - Anti-CD47 x anti-mesothelin antibodies and methods of use thereof (2022-03-01),

8. 11203646 - Anti-CD3 epsilon antibodies and methods of use thereof (2021-12-21),

9. 11059910 - Anti-CD47 antibodies and methods of use thereof (2021-07-13),

10. 10982004 - Anti-TLR4 antibodies and uses thereof (2021-04-20),

11. 10844132 - Neutralizing antibodies and methods of use thereof (2020-11-24),

12. 10759862 - Anti-IL-6/IL-6R antibodies and methods of use thereof (2020-09-01),

13. 10759858 - Anti-CD3 antibodies and methods of use thereof (2020-09-01),

14. 10689461 - Antibody dual display dual compositions and methods of use thereof (2020-06-23),

15. 10689441 - Anti—TLR4 antibodies and methods of use thereof (2020-06-23),

NovImmune SA is a Swiss biotechnology company that specializes in the research, development, and commercialization of therapeutic antibodies for the treatment of immune-related disorders and cancer. With a focus on novel antibody-based drugs, NovImmune aims to provide breakthrough therapies that address unmet medical needs. The company collaborates with leading academic institutions and pharmaceutical partners to advance its drug pipeline and bring innovative treatments to patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

64 Patents

#8 in Geneva

#248 in Switzerland

#11,189 in the World

Geneva, Switzerland

Novimmune Sa

Forward Citations = 409

51 inventors:

Greg Elson (35 out of 36 patents)

Nicolas Fischer (31 out of 32 patents)

Olivier Leger (26 out of 28 patents)

4. Marie Kosco-Vilbois (24 out of 30 patents)

5. Krzysztof Masternak (13 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…